


PROJECT MEMO

CereBree	
Vertical AI Infrastructure / Enterprise & Healthcare Intelligence	Links: Pitch Deck Tokenomics Website
Main Social Channel  30.8K followers	

AlphaMind ROUND DETAILS	
Ticker	\$CRX
Price	\$0.025 (37.5% discount to listing price)
Round FDV	\$25M
Listing FDV	\$40M (at \$0.04 listing price)
Vesting	25% TGE unlock, 6 m linear vesting

What they are building

CereBree is an on-chain cognitive layer that unifies fragmented human, enterprise, and healthcare data into context-aware AI decisions. Instead of another chatbot, it ships multiple live products connected through Cognie (its proprietary execution-focused LLM) & settled in \$CRX. The thesis: intelligence compounds as it accumulates context. **Think Anthropic, but on-chain.**

Problem & Solution

Problem: Enterprise and personal data stay siloed across systems that don't talk to each other. Generic AI tools add complexity - context is lost, models hallucinate, and insights never compound. Healthcare data is especially fragmented across providers.

Solution: CereBree unifies these datasets into one cognitive layer, using Cognie as the decision engine across enterprise, healthcare, and human-development verticals, building persistent intelligence that improves with every interaction.

Core Team



Sunil Raina,
CEO



Peter Ober,
COO



Hilmar Stock,
SVP HRX

Sunil Raina, Founder & CEO: former Microsoft executive with deep experience across enterprise technology and digital transformation.

Peter Ober, COO: 30+ years in IT Service Management, including leadership within the ServiceNow ecosystem.

Hilmar Stock, SVP HRX: veteran enterprise software executive with expertise in workforce intelligence and enterprise operations.

Backers/Partners

CereBree is partnered with Oracle (data-lake monetization & large-scale enterprise data processing per the project).

Healthcare & employment distribution partners include: NASOM (access to 250K+ autistic children via CereAura), TimesJobs (300K jobs in Phase 1, scaling toward 3M during 2026), plus Narayana Health, Amana Healthcare, University of Riyadh, KloudRAC, and GEM.

Traction

- \$1M pre-seed raised; post-revenue with €650K booked in Q2 2026.
- HRX: 3 institutional clients in DACH (incl. a large German insurer), €654K total deal value.
- HealOpera: 200 hospital partnerships onboarded.
- CereAura (public beta): NASOM partnership for 250K+ autistic children.
- CereOnco: 300+ radiology firms, pharmacies & researchers onboarding.

Token Utility

\$CRX is the economic layer across the ecosystem: platform payments, enterprise access tiers, ecosystem fee settlement, staking rewards, and governance participation. Value accrual is designed through buyback and burn mechanics, staking incentives, and treasury-driven ecosystem growth, tying ecosystem activity directly to token demand.

Deflationary mechanisms are built in; the token is deployed on Base (ERC-20) and audited by Hashlock.

Competitive Edge

- Intelligence accumulation, not model competition:** a persistent context layer that compounds, versus stateless chat tools.
- Multi-vertical architecture:** enterprise, healthcare, and human-development products share one cognitive backbone, diversifying growth paths.
- Proprietary infrastructure (Cognie):** a deeper moat than products built on publicly available models.
- Real-world distribution:** Oracle, healthcare institutions, and employment platforms provide enterprise-grade rails rather than retail-only reach.

Alphamind Analysis

CereBree stands apart from speculative AI tokens: it's post-product, post-revenue, with institutional adoption (HRX live in DACH) and a real Oracle partnership - not a roadmap promise.

The AlphaMind round terms are the edge: \$0.025 vs. a \$0.040 listing - a 37.5% discount - at just a \$25M round FDV (vs. \$40M listing FDV), with 25% TGE unlock and 6-month linear vesting. That's an early valuation at half the listing FDV, with multiple growth vectors (enterprise, healthcare, human dev) and a Cognie-powered compounding-data moat.

Breadth is the trade-off - but few AI deals pair this much real traction with these entry terms.

Risks & Opportunities

Opportunities:

- Best-in-round terms: 37.5% discount to listing, \$25M round FDV vs. \$40M listing FDV, 25% TGE unlock.
- Real revenue and live enterprise deployment (HRX) - rare among AI tokens.
- Multi-vertical strategy reduces single-market dependency and opens several growth avenues.
- Proprietary cognitive infrastructure (Cognie) + Oracle and institutional partners provide a moat and real distribution.

Risks:

- Execution complexity: running enterprise, healthcare & human-dev verticals at once.
- Enterprise sales cycles are long, delaying revenue inflection.
- Crowded, fast-moving AI sector raises competitive pressure.
- Token value depends on sustained \$CRX usage across all products; sentiment can drive TGE volatility.